$0.20
-0.02 (-8.33%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MTNB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dLNCT04662528The percent change from baseline to end of study for MAT9001 versus PlaceboRandomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: suspended | Drug: Placebo, MAT9001 (omega-3 pentaenoic acid) | Severe Hypertriglyceridemia | 0 | Aug 2022 | 2021-09-16 |
| A PK and PD Study of Two Formulations of Omega-3 One Gram CapsulesNCT02310022Bioavailability comparison after single and multiple doses over a 24 hour period at day 1 and day 14Randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Drug Omega 3, Drug Omega-3 Comparator | Hypertriglyceridemia | 48 | May 2015actual | 2020-10-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19